PDB39 EFFECT OF VARYING MODELLING ASSUMPTIONS ON THE COSTEFFECTIVENESS OF LIRAGLUTIDE 1.2 MG (AS A COMPONENT OF DUAL THERAPY) IN TYPE 2 DIABETES  by Valentine, WJ et al.
A290 13th Euro Abstracts
years, of which 20% (1.86%) discontinued and the remainder used GH intermittently. 
a one-time identiﬁ cation of nonresponders with GH dose increase of 50% was assumed 
after month 6 for children with low growth gains. The model was validated against ﬁ nal 
height gains observed in large international registries of children with IGHD. The rate 
of poor adherence was reduced by 10% and 30% in sensitivity analyses. Cost of GH 
was c32.80 per mg, and discounted at 3.5% per annum. RESULTS: The baseline cohort 
was modeled to achieve near ﬁ nal height SDS of −1.0 (± 1.23) as observed in real-life 
registries, effectively gaining 16.0 cm at a cost per cm gained of c3929. Identiﬁ cation 
of low responders increased height gain to 17.3 cm at a cost per cm gained of c3987. 
Growth gains were maximized at 18.2 cm at a cost per cm gained of c4073 when 
identifying low responders and decreasing poor adherence by 30%. CONCLUSIONS: 
Easypod® features can identify adherence proﬁ les, allowing early recognition of low 
responders, giving the potential to optimize ﬁ nal height gain and investment in GH 
therapy in IGHD.
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OBJECTIVES: Several studies have evaluated the ICER of CSII versus MDI over a 
patients’ lifetime. However, decision-makers are also concerned with shorter time 
horizons. As such, the annualized incremental cost and consequences of CSII versus 
MDI may be informative to this audience. METHODS: An economic model was 
developed using Excel spreadsheet. Deterministic data derived from various sources 
including ICES Diabetes Atlas, Statistics Canada Population, and published literature 
was used to determine the annualized costs and consequences of CSII versus MDI in 
the Province of Ontario. RESULTS: Overall, the use of CSII for all type 1 diabetic 
patients (T1DM) age 18–64 in the base-case analysis would result in savings associated 
with the event reductions of $77,885,000 per year (95% CI: 55,920,148–123,835,211). 
Assuming all T1DM patients switched to CSII, annual resource saving include: 63 
fewer AMI (95% CI: 20.8–233.0), 23 fewer major amputations (95% CI: 6.4–133.9), 
14 fewer blindness cases (95% CI: 3.6–224.5), 411 fewer dialysis years (range 329.2–
493.8), and 140 fewer hypoglycemia-related hospitalizations (range 112.3–168.5). 
Additional investments in CSII would result in a net expenditure of $4,724,000. 
However, extensive sensitivity analysis shows that there is a potential cost saving of 
$26,689,000–$41,225,000 for the province in direct medical cost assuming all 48,000 
T1DM patients adopted this technology. CONCLUSIONS: Use of CSII has demon-
strated improved glycemic control compared to MDI. Additional health beneﬁ ts 
including reductions in AMI, amputations, cataract surgery, dialysis rates, and hypo-
glycemia-related hospitalization could potentially save the health-care system both 
costs and precious resources. Sensitivity analyses suggest that under the most favorable 
conditions, adoption of CSII would be a dominant strategy (saving $41,000,000/
annum in the steady state). This analysis underestimates the CSII beneﬁ ts by ignoring 
smaller beneﬁ ts including minor amputations, costs associated with gangrene. Also, 
the effects on patient’s HR-QoL and other socioeconomic beneﬁ ts related to lost 
productivity has not been calculated.
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OBJECTIVES: Exenatide once-weekly (EQW) is a GLP-1 receptor agonist that con-
trols glucose in patients with type 2 diabetes (T2DM) and is associated with weight 
loss and improvement in cardiovascular risk factors such as blood pressure and lipids. 
We estimated the long-term clinical and ﬁ nancial beneﬁ ts of EQW compared to 
sitagliptin or pioglitazone in the United States. Pending US approval and EQW price, 
we conducted a cost-consequence analysis that excluded pharmacy costs. METHODS: 
We used the CORE Diabetes Model, a validated computer simulation model of dia-
betes progression and treatment, to project lifetime clinical outcomes and complication 
costs. Patient characteristics (mean age 52.5 years; diabetes duration 6 years; HbA1c 
8.51%; body mass index 32.12 kg·m−2) and clinical data were derived from a phase 
3 clinical trial comparing EQW to sitagliptin or pioglitazone against metformin 
background. Compared to sitagliptin and pioglitazone patients, trial patients on EQW 
had HbA1c improvement (0.63% and 0.32% points, respectively) and BMI reduction 
(0.51 kg·m−2 and 1.77 kg·m−2). Health outcomes and complication costs were dis-
counted at 3% per year. Sensitivity analyses were performed to determine how changes 
in estimated values affected results. RESULTS: Compared to sitagliptin and piogli-
tazone, EQW increased life expectancy by 0.31 years (13.80 ± 0.18 vs. 13.50 ± 0.16) 
and 0.14 years (13.80 ± 0.18 vs. 13.66 ± 0.18), respectively, and quality-adjusted 
life-years (QALY) by 0.30 (9.49 ± 0.12 vs. 9.20 ± 0.11) and 0.21 (9.49 ± 0.12 vs. 
9.28 ± 0.12). EQW was also associated with lower complication costs: Compared to 
sitagliptin and pioglitazone, EQW saved US$1654 (US$55,385 ± 1781 vs. US$57,039 
± 1848) and US$573 (US$55,385 ± 1781 vs. US$55,958 ± 1838) lifetime direct cost 
per patient. In both cases, cost savings resulted mainly from lower cumulative inci-
dence of cardiovascular diseases and neuropathic complications (e.g., ulcer, amputa-
tion). CONCLUSIONS: Over a patient’s lifetime, EQW is projected to improve health 
and decrease complication costs compared with sitagliptin or pioglitazone. Incremen-
tal cost-effectiveness ratios will depend upon EQW price.
PDB37
THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN 
THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
Kolasa K1, Niewada M2, Puelles Fernandez de Troconiz J3, Townsend R4, McEwan P4
1Bristol-Myers Squibb, Warsaw, Poland; 2HealthQuest sp z o.o., Warszawa, Poland; 
3Bristol-Myers Squibb, Braine l’Alleud, Belgium; 4CRC, Cardiff, UK
OBJECTIVES: To compare the cost-effectiveness of saxagliptin versus NPH insulin 
as second-line therapy in combination with either metformin (MET) or sulphonylurea 
(SU) after failure of monotherapy with MET or SU in a Polish setting. METHODS: 
The perspective was the Polish National Health Fund using a published ﬁ xed time 
increment, stochastic simulation model set to a 40-year time horizon. Disease progres-
sion was taken from the UKPDS 68 outcomes study. Relative effectiveness for change 
in Hba1c, weight, and hypoglycemia was determined from published trials. Costs were 
from published estimates and local data. Utilities were derived from UKPDS outcomes 
supplemented with information from published sources for hypoglycemia-, weight-, 
and injection-associated disutility. Costs and health-related effects were discounted 
annually at 5% and 3.5%, respectively. RESULTS: When compared with insulin + 
MET, saxagliptin + MET was associated with reduced severe hypoglycemia and less 
weight gain, resulting in an incremental beneﬁ t of 0.13 quality-adjusted life-years 
(QALYs) and an incremental cost-effectiveness ratio (ICER) of 27,454 zloty (PLN) 
per QALY. Treatment with saxagliptin + SU was associated with a reduction in 
symptomatic and severe hypoglycemia when compared with insulin + SU, leading to 
an incremental beneﬁ t of 0.14 QALYs and an ICER of 24,663 PLN per QALY gained. 
Key model drivers were: baseline HbA1c, treatment-associated weight gain, thresholds 
for switching treatment, age, and disutility associated with weight gain, injection fear, 
and hypoglycemia. The results were robust to various assumptions concerning inputs 
and modeling parameters, with all ICERs < 50,000 PLN per QALY gained (GDP per 
capita for 2009 was 30,000 PLN or c7300, based on 1 PLN = EUROS 0.243, June 
2010). CONCLUSIONS: Saxagliptin is cost-effective as a second-line therapy in 
combination with MET or SU in T2DM in the Polish setting. The availability of saxa-
gliptin will provide T2DM patients with an additional treatment option to insulin.
PDB38
ADDITION OF INCRETIN-THERAPY TO METFORMIN IN TYPE-2-
DIABETES MELLITUS (T2DM): COST-EFFECTIVENESS OF LIRAGLUTIDE 
VERSUS SITAGLIPTIN FROM THE PERSPECTIVE OF THE GERMAN 
STATUTORY HEALTH INSURANCE (SHI)
Schlander M1, Mentrup S2, Lund N3
1Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany; 2Novo Nordisk 
Pharma GmbH, Mainz, Germany; 3Novo Nordisk A/S, Soeborg, Denmark
BACKGROUND: The novel incretin analogue, once-daily liraglutide, mimics the 
effect of endogenous glucagons-like peptide 1 (GLP-1). Liraglutide was found to be 
signiﬁ cantly more effective than the DPP-4 inhibitor, sitagliptin (increasing the half-life 
of GLP-1 by inhibiting its degradation by DPP-4), in lowering HbA1c and weight in 
patients with T2DM (Pratley et al. 2010). OBJECTIVES: To compare, from a German 
payer’s (SHI) perspective, the long-term clinical and cost-effectiveness of liraglutide 
(1.2 mg or 1.8 mg OD) versus sitagliptin (100 mg OD), in combination with metfor-
min, in T2DM patients, based on data from the randomized clinical trial (RCT) by 
Pratley et al. 2010. METHODS: RCT data were used to populate the CORE Diabetes 
Model (CDM), calibrated to clinical study baseline characteristics and background 
mortality in a German diabetes population. Costing (direct costs only) was done from 
the SHI perspective for year 2009. a discounting rate of 3% was used for costs and 
clinical effects. For hypothetical cohorts of 1000 patients, each followed for 20 years, 
liraglutide or sitagliptin were assumed to be maintained for 5 years and patients to 
be subsequently switched to insulin. Consequences (costs and effects) were projected 
over a 20-year time horizon. RESULTS: Estimated 20-year survival rates were higher 
for liraglutide 1.8 mg (41.1%) and 1.2 mg (40.3%) compared to sitagliptin 100 mg 
(39.5%), and cumulative costs were c47,436, c45,627, and c43,298, respectively. 
Base-case ICERs were c37,163 per life-year gained for liraglutide 1.8 mg (or c48703 
for 1.2 mg) versus sitagliptin, and c20,702 (or c20,870 for liraglutide 1.2 mg) per 
QALY gained. Sensitivity analyses, including longer time horizons, different risk 
(CDM base case, Framingham study, and UKPDS) cohorts, indicated robustness of 
ﬁ ndings. CONCLUSIONS: Long-term projections combining RCT data with the 
CDM indicate an acceptable to attractive cost-effectiveness of liraglutide compared to 
sitagliptin (both plus metformin) according to currently prevailing standards.
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OBJECTIVES: To compare the effect of different sets of modeling assumptions on the 
cost-effectiveness of liraglutide 1.2 mg, as a component of dual therapy in type 2 
diabetes. METHODS: Data from three published clinical trials were used as the basis 
of the modeling analysis, comparing: liraglutide 1.2 mg versus rosiglitazone 4 mg, 
both added to glimepiride (Marre 2009); liraglutide 1.2 mg versus glimepiride 4 mg, 
both added to metformin (Nauck 2009); and liraglutide 1.2 mg versus sitagliptin 
100 mg, both added to metformin (Pratley 2010). The published and validated CORE 
Diabetes Model was used to simulate the progression of type 2 diabetes and predict 
costs (in 2009 Pounds Sterling [£]) and quality-adjusted life-years (QALYs) over 
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patients’ lifetimes. Duration of treatment was assumed to be 5 years, before switching 
to a basal insulin regimen. Changes were made to the base-case assumptions. First, 
the utility change per BMI unit gained (in patients with a BMI > 25 kg/m2) was 
decreased from −0.01 to −0.0061. Second, the treatment duration was increased from 
5 to 10 years. All other variables were kept constant. RESULTS: In the comparison 
with rosiglitazone, liraglutide was associated with a base-case incremental cost-effec-
tiveness ratio (ICER) of £6226 per QALY gained, which increased to £7545 with BMI 
utility changes and to £16,477 when the treatment duration was increased. Similar 
increases were seen for comparisons with glimepiride (£13,257 (base case) to £25,343 
(BMI utility change) and £38,368 (10-year treatment)) and sitagliptin (£9,851 [base 
case] to £14,616 [BMI changes] and £17,089 [10-year treatment]). CONCLUSIONS: 
Increasing the treatment duration and decreasing the impact of BMI on quality of life 
increased the ICER of liraglutide versus comparators. Liraglutide was shown to be 
cost-effective in dual therapy (assuming a threshold of £20,000 per QALY gained) 
versus rosiglitazone and sitagliptin in all three scenarios (base case, BMI utility 
changes, and 10-year treatment).
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OBJECTIVES: Analysis of the post-interventional follow-up of the UKPDS found that 
the beneﬁ ts of intensive therapy persisted even 10 years after the trial, a ﬁ nding 
consistent with “metabolic memory” (i.e., early metabolic status inﬂ uences long-term 
outcomes). We assessed the potential impact of “metabolic memory” on the cost-
effectiveness of intensive versus conventional care in Sweden. METHODS: We used 
the Economic and Health Outcomes (ECHO)-T2DM model to simulate lifetime health 
outcomes (including QALYs) and medical costs for 500 cohorts of 2000 newly diag-
nosed patients. In each cohort, patients were randomized to intensive or conventional 
care and HbA1c treatment effects corresponding to the UKPDS study were applied 
for the ﬁ rst 10 years. Consistent with ﬁ ndings from the follow-up study, HbA1c values 
were assumed to converge by year 10. Subsequently, in the intensive care arm, “meta-
bolic memory” effects (reduced risk for certain microvascular and macrovascular 
events and mortality) were applied. Two sets of “metabolic memory” effects from the 
UKPDS follow-up study were used: those observed in the sulfonylurea/insulin sub-
sample and those observed in the metformin subsample. a scenario assuming no 
“metabolic memory” effects was simulated for comparison. Unit costs were derived 
from the Swedish literature (modeling studies and a regression analysis of inpatient 
care costs based on administrative hospital data linked to the Swedish National 
Diabetes Register). RESULTS: Including “metabolic memory” had a large effect on 
the cost-effectiveness estimates. The incremental cost-effectiveness ratio declined from 
SEK2,387,292 (~c250,000) without “metabolic memory” to SEK731,308 (~c75,000) 
assuming effects from the sulfonylurea/insulin sample and to SEK445,425 (~c45,000) 
assuming effects from the metformin sample. CONCLUSIONS: These results suggest 
that good glycemic control early in the disease continuum may confer signiﬁ cant 
medical cost savings over the long term. Evaluations of the cost-effectiveness of 
intensive glycemic control in newly diagnosed patients should potentially consider the 
health and cost consequences of “metabolic memory.”
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OBJECTIVES: This study aimed to assess cost-effectiveness of treatment with liraglu-
tide added to a standard therapy with metformin (MET) or/and sulphonylurea (SU) 
compared with rosiglitazone and exenatide. METHODS: Our study used a health 
economic model (the CORE Diabetes Model) to project the long-term costs and clini-
cal outcomes of liraglutide based on clinical data from LEAD-1 trial: liraglutide + SU 
versus rosiglitazone + SU; and LEAD-6 trial: liraglutide + MET+/−SU versus exenatide 
+ MET+/−SU. The analysis was performed from the Slovak health-care services payer’s 
perspective in a 20-year time horizon. The analysis used health-state utility values 
from published sources to assess the effect of treatment on QALYs. The unit costs of 
treatment and complications were derived from published sources and ofﬁ cial tariff 
lists for health-care services paid by public payer. All ﬁ gures are shown in EUR. 
RESULTS: QALYs increased with liraglutide 1.2 mg + SU versus SU + rosiglitazone 
4 mg by 0.203. Total costs increased by c2561 resulting in incremental costs per 
QALY of c12,615. The incremental cost-effectiveness ratio for liraglutide 1.8 mg + 
MET+/−SU versus exenatide 10 μg + MET+/−SU was estimated at c24,013 per QALY 
gained (QALYs increased by 0.112). CONCLUSIONS: Using the CORE Diabetes 
Model and data from the LEAD 1 and LEAD 6 trials treatment with liraglutide is a 
cost-effective intervention compared with both rosiglitazone and exenatide. Sensitivity 
analysis showed the results are only moderately changing when altering the key 
parameters and assumptions.
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BACKGROUND: Unlike most other antihyperglycemic drugs, glucagon-like peptide 
1 (GLP-1) receptor agonists have a glucose-dependent action and promote weight loss. 
In a randomized clinical trial (RCT) over 26 weeks reported by Buse et al. (2009), the 
novel GLP-1 agonist liraglutide (1.8 mg once daily, OD) was found to be signiﬁ cantly 
more effective than exenatide (10 μg twice daily) in terms of HBA1c reduction. 
OBJECTIVES: To compare, from a German payer’s (SHI) perspective, the long-term 
clinical and cost-effectiveness of liraglutide (1.8 mg OD) versus exenatide (10 μg BID) 
in T2D patients, based on data from the randomized clinical trial (RCT) by Buse et 
al. 2009. METHODS: The CORE Diabetes Model (CDM) was applied using RCT 
data. The model was calibrated to RCT baseline characteristics and background 
mortality in a German diabetes population, applying epidemiological data from long-
term studies including UKPDS and Framingham to project morbidity and mortality 
of T2DM. Unit costs for direct costs were applied from an SHI perspective for year 
2009. a discounting rate of 3% was used for costs and clinical effects. For hypothetical 
cohorts of 1000 patients, each followed for 20 years, patients were assumed to be 
maintained on liraglutide and exenatide, respectively, for 5 years and subsequently 
switched to insulin. Costs and effects were projected over a 20-year time horizon. 
RESULTS: Estimated 20-year survival rates were higher for liraglutide 1.8 mg once 
daily (36.8%) compared to exenatide 10 μg administered twice daily (35.6%), and 
cumulative costs were c46,308 (liraglutide) and c45,025 (exenatide), respectively. 
Base-case ICERs were c16,632 per life-year gained for liraglutide versus exenatide, 
and c11,606 for liraglutide versus exenatide per QALY gained. Sensitivity analyses 
indicated robustness of ﬁ ndings. CONCLUSIONS: Long-term projections combining 
RCT data with the CDM strongly suggest an acceptable to attractive cost-effectiveness 
of liraglutide compared to exenatide according to currently prevailing standards.
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OBJECTIVES: To assess the long-term cost-effectiveness of treatment with liraglutide on 
top of standard therapy with metformin (MET) compared with sulphonylurea (SU) in 
people with type 2 diabetes. METHODS: The extensively published and validated CORE 
Diabetes Model was populated with the clinical data from LEAD 2: liraglutide + MET 
versus SU + MET. The analysis was performed from the polish health-care services payer’s 
perspective. a 20-year time horizon was chosen to reﬂ ect the costs and outcomes of dia-
betes as these are often only seen in the later stages of the disease. The analysis used 
health-state utility values from published sources to assess the effect of treatment on 
QALYs. The unit costs of treatment and complications were derived from published 
sources or based on expert opinion survey and Polish ofﬁ cial tariff lists for health-care 
services paid by public payer. All ﬁ gures are shown in EURO (1 EURO = 3.9 PLN). 
RESULTS: QALYs increased with liraglutide 1.2 mg + MET versus SU + MET by 0.191. 
Total costs increased by c3,349 resulting in incremental costs per QALY of c17,565. The 
incremental cost-effectiveness ratio for liraglutide 1.8 mg + MET versus SU + MET was 
estimated at c24,842 per QALY gained (QALYs increased by 0.207). Sensitivity analysis 
showed the results to be moderately changing when altering the key parameters and 
assumptions (for liraglutide 1.2 mg range from 12,944 to c30,275/QALY). CONCLU-
SIONS: Treatment with liraglutide is a cost-effective intervention compared with sulpho-
nylurea and is likely to represent good value for money in Polish setting.
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OBJECTIVES: This study evaluates the long-term economic consequences of saxagliptin 
versus sulfonylurea (SU, glipizide) as second-line therapy when used in combination with 
metformin (MET) after failure of monotherapy treatment with MET, in patients with 
type 2 diabetes mellitus (T2DM) in Germany. METHODS: A published discrete event 
simulation model with a ﬁ xed time increment was used and set to a 40-year (life-) time 
horizon. Disease progression was modeled using evidence from the UK Prospective 
Diabetes Study (UKPDS 68). The treatment sequence matched that of published guide-
lines, and efﬁ cacy and safety data were derived from published sources. The model 
assumes that quality-adjusted life-years (QALYs) are affected by complications and 
hypoglycaemic events over a lifetime. As such costs and utility decrements for macro- 
and micro-vascular complications, and adverse events such as severe hypoglycaemia are 
included. Costs were speciﬁ c to the German setting where SUs are generic. Costs and 
effects were discounted annually at 3%. The perspective of the national sick funds was 
taken, and recommendations from the Institute for Quality and Efﬁ ciency in Health 
Care (IQWiG) were considered. RESULTS: Treatment with saxagliptin + MET was 
